2019 - IEEE Fellow For contributions to magnetic information storage and spintronic devices
His scientific interests lie mostly in Internal medicine, Gastroenterology, Hepatitis B virus, Immunology and Hepatitis B. His studies in Gastroenterology integrate themes in fields like Hepatocellular carcinoma, Chronic hepatitis and Prospective cohort study, Surgery. Hepatitis B virus is the subject of his research, which falls under Virology.
His Hepatitis B research includes elements of Entecavir, HBsAg, cccDNA and Viral load. The concepts of his HBeAg study are interwoven with issues in Exacerbation and Seroconversion. The study incorporates disciplines such as Nucleoside analogue and Reverse-transcriptase inhibitor in addition to Lamivudine.
Ching-Lung Lai mostly deals with Internal medicine, Gastroenterology, Virology, Hepatitis B and Hepatitis B virus. His study in Internal medicine is interdisciplinary in nature, drawing from both Entecavir and Chronic hepatitis. Ching-Lung Lai has researched Gastroenterology in several fields, including Liver transplantation, Surgery, Telbivudine and Pathology.
His Virology research includes themes of Genotype and Nucleoside. His Hepatitis B research incorporates themes from Liver disease, Alanine transaminase, Seroconversion and Viral load. His research on Hepatitis B virus concerns the broader Immunology.
His primary areas of study are Internal medicine, Gastroenterology, Hepatitis B, Hepatitis B virus and Virology. His Internal medicine research integrates issues from Entecavir, HBsAg and Chronic hepatitis. His studies in Gastroenterology integrate themes in fields like Odds ratio, Cohort and Confidence interval.
His study with Hepatitis B involves better knowledge in Immunology. His Hepatitis B virus study combines topics in areas such as Viral hepatitis, Adverse effect, Pharmacology and Transplantation. His Virology study integrates concerns from other disciplines, such as RNA interference, DNA and Arc.
Ching-Lung Lai mainly investigates Internal medicine, HBsAg, Hepatitis B, Gastroenterology and Hepatitis B virus. As a member of one scientific family, he mostly works in the field of Internal medicine, focusing on Nucleoside analogue and, on occasion, Regression. He interconnects Entecavir, Viral load and Hepatitis in the investigation of issues within HBsAg.
His Hepatitis B research is under the purview of Immunology. His biological study spans a wide range of topics, including Hepatocellular carcinoma, Chronic hepatitis, Prognostic models and Fatty liver. His Hepatitis B virus study is related to the wider topic of Virology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A One-Year Trial of Lamivudine for Chronic Hepatitis B
C.-L. Lai;R.-N. Chien;N. W. Y. Leung;T.-T. Chang.
The New England Journal of Medicine (1998)
Viral hepatitis B
Ching Lung Lai;Vlad Ratziu;Man-Fung Yuen;Thierry Poynard.
The Lancet (2003)
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching Lung Lai;Daniel Shouval;Anna S. Lok;Ting Tsung Chang.
The New England Journal of Medicine (2006)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
S. K. Sarin;M. Kumar;G. K. Lau;Z. Abbas.
Hepatology International (2016)
Viral hepatitis C
Thierry Poynard;Man-Fung Yuen;Vlad Ratzin;Ching Lung Lai.
The Lancet (2003)
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Anna S.F. Lok;Ching Lung Lai;Nancy Leung;Guang Bi Yao.
Telbivudine versus lamivudine in patients with chronic hepatitis B.
Ching-Lung Lai;Edward Gane;Yun-Fan Liaw;Chao-Wei Hsu.
The New England Journal of Medicine (2007)
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Y.-F. Liaw;N. W. Y. Leung;T.-T. Chang;R. Guan.
Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
Ting Tsung Chang;Yun Fan Liaw;Shun Sheng Wu;Eugene Schiff.
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah.
The New England Journal of Medicine (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: